See image of how PANDAS damages the blood brain barrier here
Read the following research article here. Antibodies From Children With PANDAS Bind Specifically to Striatal Cholinergic Interneurons and Alter Their Activity
(Jian Xu, PhD, Rong-Jian Liu, PhD, Shaylyn Fahey, BS, Luciana Frick, PhD, James Leckman, MD,PhD, Flora Vaccarino, MD, Ronald S. Duman, PhD, Kyle Williams, MD, PhD, Susan Swedo, MD, Christopher Pittenger, MD, PhD)
Read the following research abstract here. Th17 Lymphocytes Drive Vascular and Neuronal Deficits in a Mouse Model of Postinfectious Autoimmune Encephalitis
(Maryann P. Platt, Kevin A. Bolding, Charlotte R. Wayne, Sarah Chaudhry, Tyler Cutforth, Kevin M. Franks, and Dritan Agalliu)
Read a short synopsis here.
New 2021 IVIG study shows efficacy in children
Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome
Isaac Melamed, MD, Roger H. Kobayashi, MD, Maeve O’Connor, MD, et al.
Objectives: Pediatric acute-onset neuropsychiatric syndrome (PANS) is a clinical diagnosis in children who have an acute manifestation of varied neuropsychiatric symptoms, including obsessive compulsive disorder, eating disorders, tics, anxiety, irritability, and problems with attention/concentration. PANS may develop as a result of a post infectious syndrome and may represent a new form of postinfectious autoimmunity. To test the hypothesis that multiple, consecutive infusions of intravenous immunoglobulin (IVIG) for PANS can be efficacious, a multisite, open-label study was designed.
Methods: The primary endpoint was evaluation of the efficacy of IVIG [Octagam 5%] in PANS over a period of 6 months (six infusions) based on mean changes in psychological evaluation scores using 6 different assessments, including the Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS), Clinical Global Impression of Severity, and the Parent-Rated Pediatric Acute Neuropsychiatric Symptom Scale (PANS Scale).
Results: The final cohort consisted of 21 subjects (7 per site) with moderate to severe PANS. The mean age was 10.86 years (range: 4–16 years). Results demonstrated statistically significant reductions in symptoms from baseline to end of treatment in all six assessments measured. CY-BOCS results demonstrated statistically significant reductions in obsessive compulsive symptoms ( p < 0.0001), resulting in >50% improvement sustained for at least 8 weeks after the final infusion and up to 46 weeks in a subset of subjects.
Conclusions: In PANS, which may be associated with an underlying immune dysregulation, sequential infusions of IVIG [Octagam 5%] successfully ameliorated psychological symptoms and dysfunction, with sustained benefits for at least 8 weeks, and up to 46 weeks in a subset of subjects. In addition, baseline immune and autoimmune profiles demonstrated significant elevations in a majority of subjects, which requires further evaluation, characterization, and study to clarify the potential immune dysfunction by which PANS manifests and progresses.
Read full paper here
This is a hopeful time for our children and for the future of PANS-PANDAS Treatment! Thank you for your steadfast work doctors!